id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-N-0230-0005,FDA,FDA-2002-N-0230,Agency Information Collection Activities; Announcement of OMB Approval; Postmarketing Adverse Drug Experience Reporting,Notice,Notice of Approval,2002-10-25T04:00:00Z,2002,10,2002-10-23T04:00:00Z,,2025-04-23T14:03:36Z,02-26914,0,0,0900006480497973
FDA-2002-N-0230-0004,FDA,FDA-2002-N-0230,Agency Information Collection Activities; Announcement of OMB Approval; Postmarketing Adverse Drug Experience Reporting,Notice,Notice of Approval,2002-10-25T04:00:00Z,2002,10,2002-10-23T04:00:00Z,,2025-04-23T14:00:44Z,02-26914,0,0,0900006480497970
FDA-2002-N-0230-0003,FDA,FDA-2002-N-0230,Agency Information Collection Activities; Submission for OMB Review; Comment Request; Postmarketing Adverse Drug Experience Reporting,Notice,General Notice,2002-07-23T04:00:00Z,2002,7,2002-07-22T04:00:00Z,2002-08-22T03:59:59Z,2025-04-23T13:56:54Z,02-18462,0,0,0900006480497969
FDA-2002-N-0230-0002,FDA,FDA-2002-N-0230,Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Drug Experience Reporting,Notice,General Notice,2002-02-26T05:00:00Z,2002,2,2002-02-25T05:00:00Z,2002-04-27T03:59:59Z,2025-04-23T13:39:28Z,02-4456,0,0,0900006480497959
FDA-2002-N-0230-0001,FDA,FDA-2002-N-0230,Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Drug Experience Reporting,Notice,General Notice,2002-02-26T05:00:00Z,2002,2,2002-02-25T05:00:00Z,2002-04-27T03:59:59Z,2025-04-23T13:34:45Z,02-4456,0,0,090000648049792c